A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
The goal of this clinical research study is to learn if PV-10 when given in combination with pembrolizumab can help to control metastatic melanoma. The safety of PV-10 will also be studied.
Disease Group: Melanoma
Treatment Agent: Pembrolizumab
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Provectus Biopharmaceuticals, Inc.
Primary Objectives The primary objective of the initial, single-arm Phase 1b portion of the study, is to assess safety and preliminary efficacy (objective response rate (ORR) and progression free survival (PFS)) of the combination (i.e., PV-10 + pembrolizumab) in treating metastatic melanoma. Potential immunomodulatory impact of study treatment will also be assessed. The primary objective of the randomized controlled Phase 2 portion of the study is to assess progression free survival, objective response rate, overall survival and safety of the combination (i.e., PV-10 + pembrolizumab) vs. standard care (i.e., pembrolizumab alone) in treating metastatic melanoma. Efficacy will be assessed by comparison of outcome in all intent-to-treat (ITT) subjects in the two study treatment arms.
IRB Review and Approval Date: 04/26/2016
Recruitment Status: Open
Projected Accrual: 144
1) Age 18 years or older, male or female.
2) Histologically or cytologically confirmed diagnosis of melanoma.
3) Stage IV melanoma for which surgery is not recommended.
4) At least 1 cutaneous or subcutaneous Injectable Lesion with longest diameter at least 5 mm.
5) A minimum of 1 measurable Target Lesion (i.e., >/= 10 mm longest diameter).
6) Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1.
7) Clinical Laboratories: a) Absolute neutrophil count (ANC) >/= 1.5 x 10^9/L and platelet count >/=100 x 10^9/L. b) Estimated creatinine clearance (CrCl, by Cockroft-Gault formula) or estimated glomerular filtration rate (eGFR) >/= 30 mL/min/1.73 m^2. c) Total bilirubin </= 3 times the upper limit of normal (ULN). d) Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) </= 5 times the upper limit of normal (ULN).
8) Thyroid function abnormality </= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2.
1) Untreated or clinically active melanoma brain metastases. 1a)
Subjects with </= 3 brain metastases and each </= 1 cm size that
were treated with either surgical resection and/or radiation therapy are
eligible for study participation provided (a) there is no evidence of
progressive central nervous system (CNS) disease on brain imaging at
least 30 days after definitive treatment and (b) the subject is not
taking prednisone at >10 mg or equivalent daily. 1b) Subjects with
> 1 cm or > 3 in number treated brain metastases are eligible for
study participation provided (a) there is no evidence of progressive CNS
disease on brain imaging at least 90 days after treatment with surgery
and/or radiation therapy and (b) if the subject is not taking prednisone
at >10 mg or equivalent daily.
2) Prior treatment with PV-10 or any anti-PD-1 antibody. Subjects previously treated with any anti-PD-L1 antibody are eligible for study participation.
3) Prior cancer therapy or anti-cancer vaccine within 4 weeks of initial study treatment.
4) Known sensitivity to any of the products or components, such as rose bengal disodium or iodine.
5) Concurrent or Intercurrent Illness: a) History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other systemic autoimmune disease. b) Evidence of clinically significant immunosuppression. c) Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity. d) Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than 200 meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity. e) Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject’s safety or compliance or interfere with interpretation of study results. f) Uncontrolled thyroid disease or cystic fibrosis. Continued in Exclusion # 6.
6) Continued from Exclusion # 5: Concurrent or Intercurrent Illness: g) Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders. h) Malignancy other than melanoma within 2 years of enrollment except for: adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer.
7) Pregnancy: a) Female subjects who are pregnant or lactating. b) Female subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment. c) Female subjects of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) who are not using highly effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures). d) Male subjects who are unwilling to use acceptable method of effective contraception.
8) Subjects unable to comprehend and give informed consent are excluded.